US Patent
US8476268 — Pyrrolidine-1,2-dicarboxamide derivatives
Composition of Matter · Assigned to Novartis AG · Expires 2029-09-10 · 3y remaining
Vulnerability score
18/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects a compound of formula (I) or a salt thereof, used in the treatment of diseases alleviated by inhibition of phosphatidylinositol 3-kinase.
USPTO Abstract
The present invention relates to a compound of formula (I) or a salt thereof, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.
Drugs covered by this patent
- Piqray (alpelisib) · Novartis
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.